Meeting Banner
Abstract #1932

RRx-001 Oxidation of Redox Sensitive Protein Thiols in Tumors Measured by Gd-LC7-SH Enhanced MRI In Preclinical Tumor Models

Natarajan Raghunand 1 , Jan Scicinski 2 , Bryan Oronsky 2 , Bhumasamudram Jagadish 3 , Eugene A Mash 3 , and Ronald L Korn 4

1 Cancer Imaging & Metabolism, Moffitt Cancer Center, Tampa, Florida, United States, 2 RadioRx Pharmaceuticals, Mountain View, California, United States, 3 Dept. of Chemistry & Biochemistry, The University of Arizona, Tucson, Arizona, United States, 4 Imaging Endpoints LLC, Scottsdale, Arizona, United States

We have investigated the kinetics of T1-shortening produced in 3 pre-clinical tumor xenograft models by Gd-LC7-SH, a DOTA-thiol complex of gadolinium. Mice were imaged before and at multiple time points following treatment with RRx-001, a novel anticancer agent that perturbs tumor redox status. Gd-LC7-SH spontaneously binds to macromolecular thiol targets following i.v. administration, producing prolonged shortening of tumor T1 in untreated animals. Following treatment with RRx-001 the washout of Gd-LC7-SH from tumors was markedly faster, consistent with the proposed glutathione-depleting mechanism of action of the drug. Use of Gd-LC7-SH-enhanced MRI as a pharmacodynamic marker of RRx-001 action is discussed.

This abstract and the presentation materials are available to members only; a login is required.

Join Here